Africa Tuberculosis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Africa · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$39.0 MnPlaceholder estimate
Estimate 2025$41.8 Mn1.6% of the global market
Projected 2034$78.2 Mn 87%Adds $36.4 Mn over 9 forecast years
CAGR 2025–20347.2%Faster than 10% of 173 Medical Devices markets here
Key players5
Africa is 1.62% of the global market.
Among regions, the largest is North America at $1.30 Bn.
94 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Africa Tuberculosis Diagnostics Market Analysis Executive Summary
Tuberculosis diagnostics find TB infection and disease using skin tests, blood tests, molecular tests and chest X-ray reading.
Key segments of the tuberculosis Diagnostics market include test (Molecular Tests, Interferon Gamma Release Assays and Skin Tests) and setting (Hospitals, TB Programs and Point of Care).
Africa Tuberculosis Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Africa Tuberculosis Diagnostics Market Dynamics
Market Growth Drivers
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Opportunity
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the tuberculosis Diagnostics market room to grow, especially in emerging markets.
Market Restraints
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the tuberculosis Diagnostics market.
Competitive Landscape for Tuberculosis Diagnostics Market in Africa
The tuberculosis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Tuberculosis Diagnostics Market in Africa
Tuberculosis Diagnostics in Africa: rules, payment and research
The African Medicines Agency (AMA) treaty covers medical devices and diagnostics as well as medicines; national regulators still approve products.[1] In some of the countries we cover here, medical devices are regulated by EDA (Egypt)[2], PPB (Kenya)[3] and SAHPRA (South Africa)[4]. How care is paid for in some of these countries: universal health insurance (Egypt)[5], the SHA (Kenya)[6] and planned National Health Insurance (South Africa)[7]. ClinicalTrials.gov lists 94 studies on Tuberculosis Diagnostics that are recruiting, active or about to start in Africa.[8]
[8]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how tuberculosis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Africa.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Cepheid (Danaher)
7.2 QIAGEN
7.3 Molbio Diagnostics
7.4 Qure.ai
7.5 Revvity
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The tuberculosis Diagnostics market can be segmented based on various criteria, including test, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Tuberculosis Diagnostics right now, from free public sources.
Clinical trials
94 active trials in Egypt, South Africa, Kenya, Nigeria, Ethiopia, DR Congo, Uganda, Tanzania, Niger, Mozambique, Sudan, Malawi, Zambia, Mali, Burkina Faso, Ghana and Morocco
Recruiting, about to start, or running now. Counted across the 17 countries we report on in Africa.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Tuberculosis Diagnostics market in Africa?
Placeholder estimate: about $41.8 Mn in 2025, rising to about $78.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Tuberculosis Diagnostics market in Africa growing?
Placeholder estimate: about 7.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Tuberculosis Diagnostics market report cover?
The report splits the market by test (Molecular Tests, Interferon Gamma Release Assays, Skin Tests, Sputum Smear and more), setting (Hospitals, TB Programs, Point of Care) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Tuberculosis Diagnostics market?
Key players include Cepheid, Qiagen N.V., Molbio Diagnostics, Qure.ai and Revvity.
What is driving the Tuberculosis Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Who regulates Tuberculosis Diagnostics in Africa?
The African Medicines Agency (AMA) treaty covers medical devices and diagnostics as well as medicines; national regulators still approve products. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Tuberculosis Diagnostics are running in Africa?
94 studies are recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Tuberculosis Diagnostics?
PubMed lists 80 papers on Tuberculosis Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
France
UK
Italy
Ecuador
Spain
Brazil
India
Saudi Arabia
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Roche